Acetazolamide Tablets IP 250 mg Exporter in India – Healthy Inc

Acetazolamide Tablets IP 250 mg | Exporter
Product image for Acetazolamide Tablets IP 250 mg Exporter; regulatory dossiers & international shipping.
Product Information
| Generic Name | Acetazolamide |
|---|---|
| Manufacturer | Healthy Life Pharma Pvt. Ltd. |
| HSN Code | 30049081 |
| Pharmacopoeia | IP |
| Product Type | Tablet |
| Category | Diuretic and Antiglaucoma Preparations |
| Subcategory | Carbonic Anhydrase Inhibitors |
| Active Ingredient | Acetazolamide |
| Strength | 250 mg |
| Dosage Form | Tablet |
| Pack Size | 10 x 10 Tablets / Box (Alu-Alu / Blister) |
| Route of Administration | Oral |
| Prescription Required | Yes |
| Therapeutic Category | Ophthalmologicals / Diuretics - Carbonic Anhydrase Inhibitors |
Medicine Details & Safety
| Short Description | Healthy Inc invites international procurement enquiries for Acetazolamide Tablets IP 250 mg manufactured by Healthy Life Pharma. Importers and overseas distributors can submit destination-country requirements for assessment of registration documentation, export artwork and shipment feasibility. | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Approved Uses / Indications | 1. Open-Angle Glaucoma: Chronic simple open-angle glaucoma and secondary glaucoma as adjunctive therapy. 2. Acute Angle-Closure Glaucoma: Preoperative short-term management to rapidly decrease intraocular pressure. 3. Acute Mountain Sickness (AMS): Prophylaxis and symptomatic treatment in high-altitude ascents. 4. Edema: Adjunctive management of abnormal fluid retention in congestive heart failure and drug-induced edema. 5. Epilepsy: Adjunctive treatment of generalized tonic-clonic, absence, or partial seizures. | ||||||||||||||||||||||||
| Full Description | Healthy Inc invites international procurement enquiries for Acetazolamide Tablets IP 250 mg manufactured by Healthy Life Pharma. Importers and overseas distributors can submit destination-country requirements for assessment of registration documentation, export artwork and shipment feasibility. Product technical specifications
Product technical specifications
Export regulatory and dossier readinessIdentify the destination authority and registration pathway. Request confirmation of CTD or ACTD dossier availability, COPP, Free Sale Certificate and current GMP documentation as applicable. Confirm COA and analytical files for the proposed product and market.Climatic zone stability and export artworkFor Acetazolamide Tablets IP 250 mg, request stability evidence appropriate to the importing market, including Zone IVb where required. Confirm shelf life, storage conditions and multilingual carton, blister and leaflet artwork against approved documentation.Global logistics and trade termsSpecify the destination, shipment size and required delivery window. Evaluate air freight or LCL/FCL sea freight from Mumbai where feasible. Agree EXW, FOB, CIF or CIP as appropriate to the transport mode and contract; confirm freight, insurance and customs responsibilities.International buyer requirementsEnquiries may identify Africa, LATAM, Middle East, CIS or APAC as target regions. Market authorization, import permits, document availability and shipment acceptance must be confirmed for each country; this is not a statement of existing registrations. | ||||||||||||||||||||||||
| Dosage Instructions | Dosage depends upon the target indication: - Open-Angle Glaucoma: 250 mg (1 tablet) one to four times daily (250 mg to 1,000 mg/day in divided doses). - Acute Angle-Closure Glaucoma: 250 mg every 4 hours or initial 500 mg followed by 250 mg every 4 to 6 hours. - Acute Mountain Sickness: 125 mg to 250 mg twice daily, starting 24 to 48 hours prior to ascent and continued for 48 hours at summit altitude. - Edema / Diuresis: 250 mg to 375 mg once daily in the morning on alternate days or consecutive 2-day cycles to avoid refractory tolerance. | ||||||||||||||||||||||||
| Side Effects | Common (1-10%): Paresthesias (tingling/numbness in fingers and toes), polyuria, transient taste alteration (dysgeusia, carbonated beverages taste flat), fatigue, mild nausea. Uncommon (0.1-1%): Mild metabolic acidosis, electrolyte imbalances (hypokalemia, hyponatremia), loss of appetite, somnolence, confusion. Rare (<0.1%): Severe sulfonamide-type allergic reactions, Stevens-Johnson syndrome, agranulocytosis, aplastic anemia, nephrolithiasis (calcium kidney stones). | ||||||||||||||||||||||||
| Warnings and Precautions | Acid-Base & Electrolyte Balance: Prolonged therapy may lead to hyperchloremic metabolic acidosis and severe hypokalemia; monitor serum electrolytes regularly. Sulfonamide Cross-Reactivity: Potential for severe cutaneous adverse reactions (SJS/TEN) and hematologic dyscrasias. Hepatic Impairment: Strictly contraindicated in severe cirrhosis due to increased risk of precipitating hepatic encephalopathy. | ||||||||||||||||||||||||
| Contraindications | 1. Known hypersensitivity to acetazolamide or other sulfonamide derivatives. 2. Marked hepatic failure, cirrhosis, or risk of hepatic encephalopathy. 3. Severe renal impairment (GFR < 10 mL/min). 4. Depressed sodium or potassium serum levels (hyponatremia, hypokalemia) and hyperchloremic acidosis. 5. Adrenocortical insufficiency (Addison's disease). 6. Long-term use in chronic non-congestive angle-closure glaucoma. | ||||||||||||||||||||||||
| Drug Interactions | 1. High-Dose Aspirin (Salicylates): Concomitant use can cause severe metabolic acidosis and increase acetazolamide central nervous system toxicity; avoid combination. 2. Digoxin / Cardiac Glycosides: Acetazolamide-induced hypokalemia significantly increases the risk of digitalis toxicity and life-threatening arrhythmias. 3. Antidiabetic Agents (Metformin / Sulfonylureas): May potentiate hypoglycemia or worsen metabolic acidosis risk. 4. Lithium: Acetazolamide promotes renal excretion of lithium, significantly reducing its therapeutic blood levels. 5. Quinidine & Amphetamines: Urinary alkalinization delays renal excretion, elevating blood levels and toxicity. |
Frequently Asked Questions
| Question | Answer |
|---|---|
| Which registration documents can be requested for Acetazolamide Tablets IP 250 mg? | Specify CTD/ACTD, COPP, FSC, COA and stability requirements for availability review. |
| Is Zone IVb data available for Acetazolamide Tablets IP 250 mg? | Request confirmation for the exact formulation and packaging configuration. |
| Can export artwork be multilingual for Acetazolamide Tablets IP 250 mg? | Provide the required languages and approved regulatory artwork for review. |
| Which shipping terms can be discussed for Acetazolamide Tablets IP 250 mg? | EXW, FOB, CIF and CIP may be evaluated according to shipment mode and agreement. |
| How do I obtain an export quotation for Acetazolamide Tablets IP 250 mg? | Provide destination country, quantity, documentation requirements and preferred trade terms. |
